Trials / Completed
CompletedNCT03553316
Drug-Drug Interaction Between PK101-001 and PK101-002
A Randomized, Open Labeled, Multiple Dose, 2-Sequence, 2-Period Cross-over Phase 1 Study to Evaluate the Drug-Drug Interaction of PK101-001 and PK101-002 in Healthy Volunteers.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 49 (actual)
- Sponsor
- PMG Pharm Co., Ltd · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Accepted
Summary
To evaluate the drug-drug interaction of PK101-001 and PK101-002 in healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PK101-002 | -(Single) PK101-002 |
| COMBINATION_PRODUCT | PK101 | -(Combination) PK101-001, PK101-002 |
Timeline
- Start date
- 2019-02-28
- Primary completion
- 2019-03-22
- Completion
- 2019-04-24
- First posted
- 2018-06-12
- Last updated
- 2019-05-24
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03553316. Inclusion in this directory is not an endorsement.